Strategies and challenges for the next generation of antibody–drug conjugates
A Beck, L Goetsch, C Dumontet… - Nature reviews Drug …, 2017 - nature.com
Antibody–drug conjugates (ADCs) are one of the fastest growing classes of oncology
therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) …
therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) …
The next generation of antibody drug conjugates
F Mack, M Ritchie, P Sapra - Seminars in oncology, 2014 - Elsevier
Antibody-drug conjugates (ADCs) represent a promising therapeutic modality for the clinical
management of cancer. The recent approvals of brentuximab vedotin and ado-trastuzumab …
management of cancer. The recent approvals of brentuximab vedotin and ado-trastuzumab …
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
K Tsuchikama, Z An - Protein & cell, 2018 - academic.oup.com
The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody
conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a …
conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a …
Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry
JR McCombs, SC Owen - The AAPS journal, 2015 - Springer
Antibody drug conjugates (ADCs) have emerged as an important pharmaceutical class of
drugs designed to harness the specificity of antibodies with the potency of small molecule …
drugs designed to harness the specificity of antibodies with the potency of small molecule …
Site-specific antibody drug conjugates for cancer therapy
S Panowski, S Bhakta, H Raab, P Polakis, JR Junutula - MAbs, 2014 - Taylor & Francis
Antibody therapeutics have revolutionized the treatment of cancer over the past two
decades. Antibodies that specifically bind tumor surface antigens can be effective …
decades. Antibodies that specifically bind tumor surface antigens can be effective …
Site-specific antibody–drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development
P Agarwal, CR Bertozzi - Bioconjugate chemistry, 2015 - ACS Publications
Antibody–drug conjugates (ADCs) combine the specificity of antibodies with the potency of
small molecules to create targeted drugs. Despite the simplicity of this concept, generation of …
small molecules to create targeted drugs. Despite the simplicity of this concept, generation of …
Antibody–drug conjugates for cancer treatment
JM Lambert, A Berkenblit - Annual review of medicine, 2018 - annualreviews.org
The concept of exploiting the specific binding properties of monoclonal antibodies as a
mechanism for selective delivery of cytotoxic agents to tumor cells is an attractive solution to …
mechanism for selective delivery of cytotoxic agents to tumor cells is an attractive solution to …
Antibody–drug conjugates: an emerging concept in cancer therapy
RVJ Chari, ML Miller… - Angewandte Chemie …, 2014 - Wiley Online Library
Traditional cancer chemotherapy is often accompanied by systemic toxicity to the patient.
Monoclonal antibodies against antigens on cancer cells offer an alternative tumor‐selective …
Monoclonal antibodies against antigens on cancer cells offer an alternative tumor‐selective …
Antibody-drug conjugates: design, formulation and physicochemical stability
SK Singh, DL Luisi, RH Pak - Pharmaceutical research, 2015 - Springer
The convergence of advanced understanding of biology with chemistry has led to a
resurgence in the development of antibody-drug conjugates (ADCs), especially with two …
resurgence in the development of antibody-drug conjugates (ADCs), especially with two …
Methods to make homogenous antibody drug conjugates
Antibody drug conjugates (ADCs) have progressed from hypothesis to approved
therapeutics in less than 30 years, and the technologies available to modify both the …
therapeutics in less than 30 years, and the technologies available to modify both the …